Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Combining local consolidative therapy (LCT) with nivolumab-ipilimumab immunotherapy failed to improve survival in metastatic non-small cell lung cancer (NSCLC), according to the phase III LONESTAR trial. Overall survival was numerically better with immunotherapy alone — 52.8 months vs. 43.2 months. The trial was closed early for futility after enrolling just 166 patients.
Adding local consolidative therapy (LCT) — radiation or surgery — on top of dual immunotherapy didn't move the needle for patients with metastatic non-small cell lung cancer (NSCLC), and may have actually made things worse. Results from the phase III LONESTAR trial, presented at the World Conference on Lung Cancer in Seoul, showed that overall survival (OS) trended in favor of nivolumab-ipilimumab alone, and the trial was closed early for futility.
The findings were especially striking in patients with oligometastatic disease — a group where LCT has historically shown promise. Even there, the immunotherapy-alone arm outperformed the combination, with a median OS of 75.8 months vs. 42.0 months. Researchers also flagged a potential culprit: mediastinal radiation may have triggered lymphopenia, blunting the immune response that makes dual immunotherapy effective in the first place.
By the Numbers:
Why it matters: These results challenge the assumption that "more treatment is better" in metastatic NSCLC. Clinicians should not routinely add LCT after dual immunotherapy induction outside of a clinical trial setting.
